# Xynomic Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xynomic-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.xynomicpharma.com
- Latest round: Series B (Jun 1, 2018)
- Investors on record: 4

## About

Xynomic Pharmaceuticals, Inc. is engaged in the development and commercialization of oncology therapeutics, focusing on innovative treatments for various cancers through advanced drug candidates.Xynomic Pharmaceuticals focuses on developing cutting-edge oncology therapeutics and is headquartered in Shanghai, China. The company was founded by Yinglin Xu, who has a history of founding other ventures in the pharmaceutical space. In June 2018, Xynomic completed a SERIES B financing round, receiving funding from investors such as Hakim Unique Internet Co., Ltd. and Northern Light Venture Capital, marking a significant investment target that supports its strategic operations.Xynomic Pharmaceuticals Holdings, Inc. specializes in the development and commercialization of advanced oncology therapeutics, with a primary focus on its lead drug candidate, Abexinostat. This drug aims to inhibit pathways tied to tumor growth and is currently being tested for efficacy in patients with follicular lymphoma and kidney cancer, as well as in combination with established therapies like Keytruda®. Xynomic operates across various regions, including China and the United States, providing solutions to a diverse clientele, including hospitals and oncology clinics.The revenue structure for Xynomic Pharmaceuticals mainly derives from clinical development activities and partnerships with healthcare providers and research institutions. Revenue is generated through the provision of proprietary therapies in the oncology sector, often facilitated by licensing agreements and collaborative development arrangements. The flagship product, Abexinostat, plays a crucial role in the company's revenue strategy, catering to specific oncology patient needs.Xynomic Pharmaceuticals is committed to expanding its product offerings and market reach. The company plans to launch new products targeting additional cancer types in the upcoming years, ensuring that they meet the evolving needs of patients. The most recent financing round in June 2018, which raised an undisclosed amount from multiple investors, will help bolster its development efforts and support entry into new geographic markets, including further expansions within Asia and the United States.

## Funding rounds

- Series B, Jun 1, 2018 — NLVC, Hakim Unique Internet Co., Ltd., Prosperico Ventures, Zhongshan Bison Healthcare Investment

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B
- Hakim Unique Internet Co., Ltd. — Series B
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Series B
- Zhongshan Bison Healthcare Investment — Series B